JNJ Add to watchlist
$248.61 15.12 (-5.73%)
After Hours: $248.61 +0.00 (+0.00%)
Last updated: Oct 13, 2026 22:18
52-Week Range
$248.61
$184.66 $248.61 $281.07

Fundamentals Overview

Johnson & Johnson is in the middle of its 52-week range with premium valuation, experiencing significant downward pressure today.

Valuation premium

P/E 30.1 PEG 3.44 P/B 7.32 P/S 6.46

Profitability

ROE 25.74% Net margin 21.5%

Risk (Beta)

0.2 — lower vol

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Hold — 61% confidence Risk: Lower Volatility — Beta 0.2. Diversify and only invest what you can afford to lose.

Supporting (Buy):

Volume above average

Pressures (Sell):

P/E 30.1 (premium) · PEG 3.44

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$635.56B
P/E (TTM)
30.08
EPS (TTM)
N/A
Dividend Yield
3.12%
52-Week Range
$184.66 - $281.07
Volume vs Avg
2.56x
256% of avg (High)
Beta
0.2

About

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
Sector: Healthcare
Headquarters: US
Website: www.jnj.com
Beta: 0.2 (Less volatile than market)

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

Metric Value
Valuation
P/E (TTM) 30.08
PEG (TTM) 3.44
P/B (TTM) 7.32
P/S (TTM) 6.46
Profitability
ROE (TTM) 25.74%
ROA (TTM) 10.6%
Revenue growth (YoY) N/A
Net margin (TTM) 21.48%
Gross margin (TTM) 68.05%
Operating margin (TTM) 25.73%
Debt to equity (TTM) 0.58

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for JNJ.

Loading analyst coverage...

Price target data is not available for this symbol from the current data source.

Stock Grades (Institutions)

No stock grades available for this symbol.

No price targets, ratings snapshot, or grades available for this symbol.